Overview

Effect of Metformin Use on Mortality in Diabetic and Non Diabetic Patients With Sepsis and Septic Shock.

Status:
Not yet recruiting

Trial end date:
2025-01-31

Target enrollment:
0

Participant gender:
All

Summary

We aimed to determine if metformin use in both diabetic and non diabetic patients with sepsis and septic shock affects 28 day mortality and its effect on inflammatory markers. Plasma rennin, serum lactate concentration and IL6 will be measured for predicting 28 days in-hospital mortality in patients with sepsis.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assiut University

Treatments:

Metformin

Criteria

Inclusion Criteria:

- both sexes aged ≥18 years old complaining of sepsis or septic shock with anticipated
stay >24 hours, and signed informed consent by patient or next-of-kin.

Exclusion Criteria:

- Age less than 18 years old, chronic kidney disease stage IV/V (baseline eGFR
<30ml/min/1.73m2), patients with acute coronary syndrome, or do not resuscitate order.
Patients could be enrolled at any point during their admission.